ClearPoint Neuro Highlights Partner Aspen Neuroscience’s RMAT Designation From FDA For Parkinson’s Therapy, Sasineprocel
Clearpoint Neuro Inc CLPT
$14.94
▲ +2.47%
(+$0.36)
📅 Earnings This Week
Open
$14.90
Prev Close
$14.58
Day Range
$14.23 – $14.97
52W Range
$8.27 – $30.10
Market Cap
$448.04M
Beta
1.25
EPS (TTM)
$-1.01
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-07-03 |
| Shares Out. | 29,990,000 |
| Website | clearpointneuro.com/ ↗ |
| Phone | 13026587581 |
| Employees | 172 |
| Revenue | $12.1M |
| Gross Profit | $7.8M |
| Net Income | -$9.6M |
| Free Cash Flow | -$26.7M |
| Total Assets | $93.4M |
| Total Liabilities | $74.6M |
| Equity | $18.8M |
About Clearpoint Neuro Inc
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
Clearpoint Neuro Inc is a publicly traded company under the ticker symbol CLPT on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)